- •Alloimmunization and iron overload are risks of red cell transfusion for SCD.
- •Prophylactic Rh and K matching of red cells is recommended for patients with SCD.
- •RH variation among African patients and donors contributes to Rh alloimmunization.
- •Immunosuppression can be tailored for severe hemolytic transfusion reactions.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Demographic and epidemiologic characterization of transfusion recipients from four US regions: evidence from the REDS-III recipient database.Transfus. 2017; vol. 57: 2903-2913https://doi.org/10.1111/trf.14370
"Healthcare Cost and Utilization Project (HCUP) Statistical Briefs," 2006.
- Transfusion reactions: prevention, diagnosis, and treatment.Lancet. 2016; vol. 388 (12 03): 2825-2836https://doi.org/10.1016/S0140-6736(15)01313-6
G.D. o H. Q. U.S Centers for Disease Control and Prevention. Atlanta and N. C. f. E. a. Z. I. D. Promotion. "The National Healthcare Safety Network (NHSN) Manual: Biovigilance Component." 〈http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf〉. (accessed June 29, 2022).
- Red cell transfusion and alloimmunization in sickle cell disease.Haematol. 2021; vol. 106 (07 01): 1805-1815https://doi.org/10.3324/haematol.2020.270546
- Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.Blood. 2012; vol. 120: 528-537https://doi.org/10.1182/blood-2011-11-327361
- Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease.Blood. 1990; vol. 76 (Oct 01) (Oct 01): 1431-1437
- Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.N Engl J Med. 1990; vol. 322: 1617-1621https://doi.org/10.1056/NEJM199006073222301
- American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.Blood Adv. 2020; vol. 4: 327-355https://doi.org/10.1182/bloodadvances.2019001143
- Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories.(Eng), Arch Pathol Lab Med. 2005; 129: 190-193https://doi.org/10.5858/2005-129-190-PMODRB
- Red blood cell alloimmunization in sickle cell disease: prevalence in 2010.Transfus. 2013; vol. 53: 704-709https://doi.org/10.1111/j.1537-2995.2012.03796.x
- High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.Blood. 2013; vol. 122: 1062-1071https://doi.org/10.1182/blood-2013-03-490623
- Relevance of RH variants in transfusion of sickle cell patients.Transfus Clin Biol. 2011; vol. 18: 527-535https://doi.org/10.1016/j.tracli.2011.09.001
- genotype matching for transfusion support in sickle cell disease.Blood. 2018; vol. 132 (09 13): 1198-1207https://doi.org/10.1182/blood-2018-05-851360
National Heart, National Institutes of Health,"Evidence-Based Management of Sickle Cell Disease Expert PanelReport," U.S. Department of Health and Human Services, 2014. [Online].Available: Evidence-Based Management of Sickle Cell Disease: Expert Panel, 2014(nih.gov).
- Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects.Br J Haematol. 2017; vol. 176 (01): 179-191https://doi.org/10.1111/bjh.14346
- Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.JAMA. 2014; vol. 312: 1033-1048https://doi.org/10.1001/jama.2014.10517
- Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline.Transfus. 2018; vol. 58 (06): 1555-1566https://doi.org/10.1111/trf.14611
- Molecular matching of red blood cells is superior to serological matching in sickle cell disease patients.Rev Bras Hematol Hemoter. 2013; vol. 35: 35-38https://doi.org/10.5581/1516-8484.20130012
- Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME).Transfus. 2011; vol. 51: 1732-1739https://doi.org/10.1111/j.1537-2995.2010.03045.x
- How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.Blood. 2018; vol. 131 (06 21): 2773-2781https://doi.org/10.1182/blood-2018-02-785964
- Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease.Hematol. 2004; vol. 9 (2004 Oct-Dec): 433-436https://doi.org/10.1080/10245330400001926
- The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.Vox Sang. 2015; vol. 108: 262-267https://doi.org/10.1111/vox.12217
- Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype.Haematol. 2014; vol. 99: e115-e117https://doi.org/10.3324/haematol.2014.104703
AABB, C. S. Cohn, Ed. Technical Manual, 20th ed.
- Marion E C.R. Lomas-Francis The Blood Group Antigen Facts Book. 2nd ed..,. Elsevier Ltd, 2004
- Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.Br J Haematol. 2015; vol. 169: 746-753https://doi.org/10.1111/bjh.13339
- Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series.Transfus. 2016; vol. 56: 107-114https://doi.org/10.1111/trf.13379
- Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.Transfus. 2019; vol. 59 (07): 2282-2291https://doi.org/10.1111/trf.15328
- Serious hazards of transfusion (SHOT) haemovigilance and progress is improving transfusion safety.Br J Haematol. 2013; vol. 163: 303-314https://doi.org/10.1111/bjh.12547
- Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.Am J Hematol. 2017; vol. 92: 1340-1348https://doi.org/10.1002/ajh.24908
- Delayed hemolytic transfusion reaction presenting as sickle-cell crisis.Ann Intern Med. 1980; vol. 93: 231-234https://doi.org/10.7326/0003-4819-93-2-231
- How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.Br J Haematol. 2015; vol. 170: 745-756https://doi.org/10.1111/bjh.13494
- Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease.Transfus. 2019; vol. 59 (02): 448-453https://doi.org/10.1111/trf.15010
- RBC antibody persistence.Transfus. 2000; vol. 40: 1127-1131https://doi.org/10.1046/j.1537-2995.2000.40091127.x
- One third of alloantibodies in patients with sickle cell disease transfused with African blood are missed by the standard red blood cell test panel.Haematol. 08 01 2021; vol. 106: 2274-2276https://doi.org/10.3324/haematol.2021.278451
- Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells.Transfus. 1997; vol. 37: 376-381https://doi.org/10.1046/j.1537-2995.1997.37497265337.x
- Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.Transfus Clin Biol. 2019; vol. 26: 130-134https://doi.org/10.1016/j.tracli.2019.03.002
- The sickle cell hemolytic transfusion reaction syndrome.Transfus. 1997; vol. 37: 382-392https://doi.org/10.1046/j.1537-2995.1997.37497265338.x
- Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.Pediatr. 2003; vol. 111 (Pt 1): e661-e665https://doi.org/10.1542/peds.111.6.e661
- Hyperhemolysis syndrome in anemia of chronic disease.Transfus. 2005; vol. 45: 1930-1933https://doi.org/10.1111/j.1537-2995.2005.00608.x
- Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review.Transfus Med Rev. 2010; vol. 24: 64-67https://doi.org/10.1016/j.tmrv.2009.09.006
- Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review.Transfus. 2008; 48: 1231-1238https://doi.org/10.1111/j.1537-2995.2008.01693.x
- What do we mean by "Hyperhaemolysis" and what is the cause?.Transfus Med. 2012; 22: 77-79https://doi.org/10.1111/j.1365-3148.2012.01151.x
- A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease.Am J Clin Pathol. 2014; vol. 141: 256-261https://doi.org/10.1309/AJCP47QAAXTOZEKJ
- Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death.Transfus. 2009; vol. 49: 1785-1792https://doi.org/10.1111/j.1537-2995.2009.02199.x
- Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients.Blood. 25 2016; vol. 127: 1062-1064https://doi.org/10.1182/blood-2015-09-669770
- Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.Transfus. 2015; vol. 55: 623-628https://doi.org/10.1111/trf.12876
- Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: the experience so far.Transfus. 2022; vol. 62 (03): 546-550https://doi.org/10.1111/trf.16805
- Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.Br J Haematol. 2019; vol. 186 (09): e212-e214https://doi.org/10.1111/bjh.16103
- Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.Transfus. 2015; vol. 55: 2398-2403https://doi.org/10.1111/trf.13144
- Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature.Transfus. 2015; vol. 55: 259-264https://doi.org/10.1111/trf.12815
- A syndrome of hypertension, convulsion, and cerebral haemorrhage in thalassaemic patients after multiple blood-transfusions.Lancet. 1978; vol. 2: 602-604https://doi.org/10.1016/s0140-6736(78)92824-6
- Blood transfusion in sickle cell disease: a cautionary tale.Lancet. 2003; 361: 1659-1660https://doi.org/10.1016/S0140-6736(03)13293-X
- Hypertension, convulsions, and cerebral haemorrhage in sickle-cell anaemia patients after blood-transfusions.Lancet. 1978; vol. 2: 1207https://doi.org/10.1016/s0140-6736(78)92193-1
- Sickle cell disease: when and how to transfuse.Hematol Am Soc Hematol Educ Program. 2016; 2016: 625-631https://doi.org/10.1182/asheducation-2016.1.625
- American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.Blood Adv. 2020; vol. 4 (04 28): 1554-1588https://doi.org/10.1182/bloodadvances.2019001142
- Time to rethink haemoglobin threshold guidelines in sickle cell disease.Br J Haematol. 2021; vol. 195 (11): 518-522https://doi.org/10.1111/bjh.17578
- Blood rheology: key parameters, impact on blood flow, role in sickle cell disease and effects of exercise.Front Physiol. 2019; vol. 10: 1329https://doi.org/10.3389/fphys.2019.01329
- The role of blood rheology in sickle cell disease.Blood Rev. 2016; vol. 30: 111-118https://doi.org/10.1016/j.blre.2015.08.005
- Arterial blood pressure and hyperviscosity in sickle cell disease.( Eng), Hematol Oncol Clin North Am. 2005; vol. 19 (vi, Oct): 827-837https://doi.org/10.1016/j.hoc.2005.08.006
A. Taher, E. Vichinsky, K. Musallam, M.D. Cappellini, and V. Viprakasit, "Guidelines for the Management of Non-Transfusion Dependent Thalassemia (NTDT) ". [Online]. Available: 〈https://thalassemia.com/documents/NTDT-TIF-guidelines.pdf〉.
- Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.Transfus. 2008; vol. 48: 1971-1980https://doi.org/10.1111/j.1537-2995.2008.01775.x
- Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.Br J Haematol. 2016; vol. 172: 122-130https://doi.org/10.1111/bjh.13791
- Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.Am J Hematol. 2012; vol. 87: 221-223https://doi.org/10.1002/ajh.22228
- Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease.Br J Haematol. 2006; vol. 135: 574-582https://doi.org/10.1111/j.1365-2141.2006.06332.x
- Chronically transfused pediatric sickle cell patients are protected from cardiac iron overload.Pedia Hematol Oncol. 2012; vol. 29: 254-260https://doi.org/10.3109/08880018.2011.630774
- Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.PLoS One. 2017; vol. 12e0172147https://doi.org/10.1371/journal.pone.0172147
- Cardiac iron overload in sickle-cell disease.Am J Hematol. 2014; vol. 89: 678-683https://doi.org/10.1002/ajh.23721
- Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia.Am J Hematol. 2005; vol. 80: 70-74https://doi.org/10.1002/ajh.20402
- "Classification and diagnosis of iron overload.Haematol. 1998; vol. 83: 447-455
- Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload.Eur J Haematol. 2010; vol. 85: 51-57https://doi.org/10.1111/j.1600-0609.2010.01449.x
- Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.J Pathol. 1975; vol. 116: 83-95https://doi.org/10.1002/path.1711160204
- Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias.Blood. 2003; vol. 101: 91-96https://doi.org/10.1182/blood-2002-06-1704
- Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.Am J Hematol. 2009; vol. 84: 480-483https://doi.org/10.1002/ajh.21456
- Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.Br J Haematol. 2006; vol. 135: 254-263https://doi.org/10.1111/j.1365-2141.2006.06277.x
- Concepts and goals in the management of transfusional iron overload.Am J Hematol. 2007; vol. 82: 1136-1139https://doi.org/10.1002/ajh.21100
- Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.Blood. 2005; vol. 105: 855-861https://doi.org/10.1182/blood-2004-01-0177
- Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis.Haematol. 1991; vol. 76 (Sep-Oct 1991): 409-413
- Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.Blood. 2009; vol. 114: 4632-4638https://doi.org/10.1182/blood-2009-02-203323
- Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.J Pedia Hematol Oncol. 2009; vol. 31: 309-312https://doi.org/10.1097/MPH.0b013e3181a1c143
- Iron chelation in thalassemia major.Clin Ther. 2015; vol. 37: 2866-2877https://doi.org/10.1016/j.clinthera.2015.10.001